Large-molecule antibody biologics have revolutionized medicine owing to their superior
target specificity, pharmacokinetic and pharmacodynamic properties, safety and toxicity …

Bispecific antibodies (bsAbs) have attracted significant attention due to their dual binding
activity, which permits simultaneous targeting of antigens and synergistic binding effects …

Monoclonal antibodies have emerged as key therapeutics. In particular, nanobodies, small,
single-domain antibodies that are naturally expressed in camelids, are rapidly gaining …

Antibody-based biotherapeutics have emerged as a successful class of pharmaceuticals
despite significant challenges and risks to their discovery and development. This review …

Introduction: In this study, we demonstrate the feasibility of yeast surface display (YSD) and
nextgeneration sequencing (NGS) in combination with artificial intelligence and machine …

Therapeutic proteins and antibodies are exposed to a variety of interfaces during their
lifecycle, which can compromise their stability. Formulations, including surfactants, must be …

We introduce IgDiff, an antibody variable domain diffusion model based on a general protein
backbone diffusion framework, which was extended to handle multiple chains. Assessing …

Engineered antibody formats, such as antibody fragments and bispecifics, have the potential
to offer improved therapeutic efficacy compared to traditional full-length monoclonal …

Specifically designed co-solvent mixtures are an efficient way to enhance the kinetics of
enzyme-catalyzed reactions without compromising enzyme stability; among them, several …

Abstract α-Synuclein (α-syn) accumulates as insoluble amyloid but also forms soluble α-syn
oligomers (αSOs), thought to be even more cytotoxic than fibrils. To detect and block the …